A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis

Psoriasis Vulgaris Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01105286
• Other study ID #: PLQ-005
• Secondary ID: 2009-017393-20
• Status: Completed
• Phase: Phase 1
• First received: April 15, 2010
• Last updated: October 24, 2013
• Start date: April 2010
• Est. completion date: June 2010

Study information

• Verified date: October 2013
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to compare the anti-psoriatic effect of eight different formulations of vitamin D analogues using a psoriasis plaque test design

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects having understood and signed an informed consent form.

• Either sex

• Age 18 years or above

• All skin types and any ethnic origin

• Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk.

Exclusion Criteria:

• Females who are pregnant, or who wish to become pregnant during the study, or who are breast feeding

• Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (which-ever is longer) for experimental biological products prior to randomisation

• Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immuno-suppressants) within the 4-week period prior to randomisation

• Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the study:

• Potent or very potent (WHO group III-IV) corticosteroids

• PUVA or Grenz ray therapy

• Subjects using one of the following topical drugs for the treatment of psoriasis within two weeks prior to randomisation and during the study:

• WHO group I-II corticosteroids (except if used for treatment of scalp psoriasis)

• Topical retinoids

• Vitamin D analogues

• Topical immunomodulators (e.g. macrolides)

• Anthracen derivatives

• Tar

• Salicylic acid

• UVB therapy

• Subjects known to be non-responder to topical vitamin D analogues (e.g., known history of no improvement or worsening of psoriasis with e.g., calcipotriol, calcitriol or tacalcitol when used according to current SmPc)

• Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4 week period prior to randomisation or longer, if the class of the substance requires a longer washout as defined above (e.g., biological treatments)

• Subjects with current participation in any other interventional clinical, based on interview of the subject

• Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

• Subjects with known or suspected hypersensitivity to component(s) of the investigational products

• Subjects with known/suspected disorders of calcium metabolism associated with hypercalcaemia

• Subjects with known severe hepatic and/or severe renal insufficiency

• Subjects with any concomitant medical or dermatological disorder(s) which might preclude accurate evaluation of the psoriasis

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Psoriasis
• Psoriasis Vulgaris

Intervention

Drug:
• Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
Once daily application

Locations

Country	Name	City	State
France	LEO Pharma site	Nice

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Clinical Score of clinical symptoms		4 weeks	No
Secondary	Clinical scores, lesions thickness		4 weeks	No